⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2568389 | 1.00 | — | — | |
| SCHEMBL2566249 | 1.00 | — | — | |
| SCHEMBL1003464 | 0.86 | POLB (0.73) | — | |
| SCHEMBL37939 | 0.86 | POLB (0.73) | — | |
| SCHEMBL2876578 | 0.86 | POLB (0.73) | — | |
| SCHEMBL1857058 | 0.85 | L3MBTL1 (0.64) | — | |
| SCHEMBL2679258 | 0.85 | L3MBTL1 (0.64) | — | |
| SCHEMBL2904191 | 0.85 | L3MBTL1 (0.64) | — | |
| SCHEMBL23533074 | 0.83 | L3MBTL1 (0.62) | — | |
| SCHEMBL17395466 | 0.82 | POLB (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228482-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER | HOTSPOT THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240199655-A1 | Immunoproteasome Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2024-06-20 | — | — | US | disclosed |
| WO-2024121753-A1 | POLQ INHIBITORS | ASTRAZENECA AB (SE) | 2024-06-13 | — | — | WO | disclosed |
| US-20240174662-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | CILAG AG (CH) | 2024-05-30 | — | — | US | disclosed |
| CN-111491938-B | Immunoproteasome inhibitors | 普林斯匹亚生物制药公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-117751115-A | Compounds, compositions, and methods of treating cancer | 热点治疗公司 | 2024-03-22 | — | — | CN | disclosed |
| US-11827656-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230364070-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ANTARES THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| CN-116997549-A | Pyrrolo [3,2-C ] pyridin-4-one derivatives for the treatment of cancer | 蝎子疗法股份有限公司 | 2023-11-03 | — | — | CN | disclosed |
| WO-2023173083-A1 | TETRAHYDROINDOLE DERIVATIVES AS EGFR AND/OR HER2 INHIBTORS USEFUL FOR THE TREATMENT OF CANCER | SCORPION THERAPEUTICS, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| US-10450296-B2 | Heterocyclic compounds useful as Pim kinase inhibitors | INCYTE CORPORATION (US) | 2019-10-22 | — | — | US | disclosed |
| US-20190142834-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. | 2019-05-16 | — | — | US | disclosed |
| US-20180282302-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION | 2018-10-04 | — | — | US | disclosed |
| US-9920032-B2 | Heterocyclic compounds useful as pim kinase inhibitors | INCYTE CORPORATION (US) | 2018-03-20 | — | — | US | disclosed |
| US-20170096411-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION | 2017-04-06 | — | — | US | disclosed |
| US-9561230-B2 | Aryl-substituted tricyclic sulfonamides as methionyl aminopeptidase 2 modulators | ZAFGEN, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-20160256469-A1 | TRICYCLIC SULFONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2016-09-08 | — | — | US | disclosed |
| US-9187494-B2 | Aryl-substituted tricyclic sulfonamides as methionyl aminopeptidase 2 modulators | ZAFGEN, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| EP-2705036-B1 | TRICYCLIC SULFONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2015-08-12 | — | — | EP | disclosed |
| US-20140073623-A1 | Tricyclic Sulfonamide Compounds and Methods of Making and Using Same | ZAFGEN, INC. (US) | 2014-03-13 | — | — | US | disclosed |